The Aarti Drugs Buyback date has been Recorded on August 4, 2023
Aarti Drugs was founded in 1984 and is part of the USD 900 million Aarti Group of Industries, having a strong R&D Division at Tarapur, Maharashtra Industrial Development Corporation (MIDC), close to production facilities.
Start your investing journey today. How do you open your own demat account for free?
Record Dates
August 4, 2023
Buyback Price
₹900 per equity share
Face Value
₹10 per share
Offer Closes On
August 17, 2023
Aarti Drugs Buyback Price
The Aarti Drugs Buyback price is ₹[900 per equity share ].
IPO Overview
Aarti Drugs Limited, established in 1984, is a renowned manufacturer of specialty chemicals and bulk drugs. With a diverse range of over 40 products, the company produces bulk actives, key intermediates, and specialty chemicals. Their product portfolio encompasses various therapeutic groups such as anti-biotic, anti-protozoal, anti-inflammatory, anti-fungal, anti-diabetic, cardio-protectant, vitamins, anti-arthritis, and sedatives. These products play a crucial role in treating life-threatening conditions as well as lifestyle-related diseases.
Aarti Drugs Share Buyback 2023 Details
| Aarti Drugs Buyback Dates | Coming soon |
| Aarti Drugs Buyback Price | INR 900 per share |
| Market Price on Buyback Approval | INR 508.5 per share |
| Buyback Premium on Market Price | 76.99% |
| Buyback Offer Size (Shares) | 6,65,000 shares |
| Buyback Offer Size (Amount) | INR 59.85 crore |
| Offer Type | Tender |
| Promoter Participation | Yes |
| Face Value | INR 10 per share |
| Listing At | NSE, BSE |
Aarti Drugs Buyback Dates (Timeline)
| Board Meeting Intimation for Buyback Proposal | 14 July 2023 |
| Buyback Approval Date | 21 July 2023 |
| Public Announcement of Buyback | Coming soon |
| Aarti Drugs Buyback Record Date | 4 August 2023 |
| Buyback Opening Date | Coming soon |
| Buyback Closing Date | Coming soon |
| Cut-off Date to receive completed tender forms by Registrar | Coming soon |
| Verification Date by the Registrar | Coming soon |
| Return of unaccepted shares by Registrar | Coming soon |
| Extinguishment of accepted shares | Coming soon |
Aarti Drugs Buyback Entitlement Ratio
| Shareholder Category | Entitlement Ratio | Entitlement Ratio (in %) |
| Small Shareholders | ||
| (less than INR 2 Lakh on record date) | – | 4.78 |
| General category | ||
| (for all other Eligible Shareholders) | – | – |
Aarti Drugs Financial Performance
| FY 2021 | FY 2022 | FY 2023 | |
| Revenue | 2,155 | 2,489 | 2,716 |
| Total Expenses | 1,714 | 2,156 | 2,410 |
| Net income | 280 | 205 | 166 |
Calculation of Investment in Buyback
| Maximum market value of a share holder as on record date | INR 2,00,000 |
| Buyback price per share | INR 900 |
| Maximum shares for small shareholder (2,00,000/900) | 223 shares * |
| Closing price of stock as on 21 July 2023 | INR 508.5** |
| Maximum amount invested in buyback (INR 508.5 x 223 shares) | INR 113,395.5 |
Aarti Drugs Buyback Acceptance Ratio
| Shares Tendered | Buyback Entitlement | Acceptance ratio | Buyback Profit | Profit in % |
| 223 | 11 | 11 (100%) | 4,306.5 | 3.80 |
| 223 | 11 | 22 (200%) | 8,613.0 | 7.60 |
| 223 | 11 | 33 (300%) | 12,919.5 | 11.39 |
Company Profile
Aarti Drugs operates nine manufacturing units in Tarapur, Maharashtra, and two manufacturing units in Sarigam, Gujarat. These facilities are predominantly GMP certified. The company has a global presence, exporting its products to more than 100 countries. Aarti Drugs has obtained approvals from various esteemed authorities including WHO-GMP, ACCREDITATION from JAPAN, IDL China, ANVISA, TGA Australia, COFEPRIS, and COS. In terms of financial performance, the company achieved a total revenue of ₹2,71,824.75 lakhs, ₹2,49,996.17 lakhs, and ₹2,15,930.50 lakhs in the years 2023, 2022, and 2021 respectively.
Registrar Info
| Name | LINK INTIME INDIA PRIVATE LIMITED |
| Phone number | +91-22-4918 6270 |
| Email ID | aartidrugs.buyback2023@linkintime.co.in |
| Website | https://linkintime.co.in/mipo/ipoallotment.html |
Contact Details
| Name | Aarti Drugs Buyback Limited |
| Phone number | +91 22 2401 9025 |
| Email ID | admin@aartidrugs.com |
| Website | https://www.aartidrugs.co.in/ |
IPO Strenghts
- Experienced promoters and a competent management team.
- Well-established relationships with a loyal customer base.
- Access to markets worldwide, enabling global reach.
IPO Weakness
- Heavy reliance on customers based in the United States.
- Need to adhere to multiple laws and regulations in these countries to ensure compliance.
- Competition from other players in the market.
